Immunome (NASDAQ:IMNM) Stock Price Up 9.5% – Still a Buy?

by · The Cerbat Gem

Shares of Immunome, Inc. (NASDAQ:IMNM – Get Free Report) shot up 9.5% on Wednesday . The stock traded as high as $18.55 and last traded at $18.71. 157,192 shares were traded during trading, a decline of 86% from the average session volume of 1,125,947 shares. The stock had previously closed at $17.09.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Wall Street Zen raised Immunome from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research report on Wednesday, October 8th. Truist Financial started coverage on shares of Immunome in a report on Monday. They issued a “buy” rating and a $36.00 price objective for the company. Guggenheim restated a “buy” rating and set a $25.00 target price on shares of Immunome in a research report on Monday, August 25th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Immunome from $23.00 to $22.00 and set an “overweight” rating for the company in a research report on Thursday, August 7th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.00.

View Our Latest Analysis on Immunome

Immunome Stock Up 3.7%

The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of -6.81 and a beta of 2.17. The business’s 50 day simple moving average is $15.98 and its 200-day simple moving average is $11.77.

Immunome (NASDAQ:IMNM – Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. On average, analysts expect that Immunome, Inc. will post -2.21 earnings per share for the current year.

Institutional Investors Weigh In On Immunome

A number of large investors have recently modified their holdings of the business. Assetmark Inc. bought a new position in shares of Immunome in the 3rd quarter valued at $39,000. BNP Paribas Financial Markets boosted its stake in Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after buying an additional 2,909 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Immunome by 121.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after buying an additional 3,802 shares in the last quarter. BIT Capital GmbH acquired a new position in Immunome during the third quarter worth about $69,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Immunome in the third quarter worth about $76,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

(Get Free Report)

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

See Also